Early research (Phase 1)Study completedNCT00000667
What this trial is testing
A Phase I/II Dose Escalation Study of Intradermal gp160 to Evaluate Safety, Delayed Type Hypersensitivity (Skin Test) Responses and Immunogenicity in Asymptomatic HIV Seropositive Patients With More Than 400 CD4+ Cells
Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 20